欧盟委员会批准 Biocon 的 Pebrilzo,为首个按 EMA 定制临床路径获批的乳腺癌生物类似药
Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach
欧盟委员会授予 Biocon 的帕妥珠单抗生物类似药 Pebrilzo 欧盟上市许可,用于 HER2 阳性乳腺癌多个疾病阶段的治疗,Biocon 称其为 EMA 定制临床路径下首个获批的生物类似药。
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
Biocon announced on November 18, 2026, that the European Commission (EC) granted marketing authorization for Pebrilzo, its biosimilar to Perjeta (pertuzumab), for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union.¹ Biocon said Pebrilzo is the first biosimilar authorized under the European Medicines Agency’s (EMA’s) new tailored clinical approach.¹
The EC decision follows the positive opinion from EMA’s Committee for Medicinal Products for Human Use (CHMP) that BioPharm International® reported in September, when Pebrilzo became the first monoclonal antibody biosimilar to receive a CHMP recommendation under the framework.
“The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon,” said Shreehas Tambe, chief executive officer and managing director of Biocon.¹ Tambe said pertuzumab becomes Biocon’s “fifth oncology biosimilar approved in both Europe and the United States.”¹
What is the tailored clinical approach?
CHMP adopted its “Reflection paper on a tailored clinical approach in biosimilar development” on March 16, 2026.² The paper examines settings in which similar clinical efficacy and safety of a biosimilar candidate and its reference product can be inferred from analytical and pharmacokinetic (PK) similarity, and it notes that comparative efficacy studies generally did not add pivotal information to biosimilarity assessments.²
Under the previous standard, developers were typically expected to run comparative efficacy studies to confirm similar clinical performance. The new approach indicates that such studies will no longer be expected for most biosimilar candidates.³ BioPharm International covered EMA’s proposal when the draft reflection paper was released, and FDA has signaled a similar shift through October 2025 draft guidance proposing that comparative efficacy studies may not be needed in some cases.
For Pebrilzo, Biocon said extensive analytical characterization and comparative clinical PK data showed the product is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.¹
The shift places more weight on the comparability work done during development. In a Q&A with BioPharm International, Zara Bukhari, a PhD scholar at the University of the Pacific, said, “Process development for biosimilars differs from other biologics and small-molecule drugs primarily due to the need to demonstrate high similarity to an existing reference product.”
What is Pebrilzo approved for?
“The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon.” Shreehas Tambe, chief executive officer and managing director, Biocon
Pebrilzo is a 420 mg concentrate for solution for infusion used in combination regimens for HER2-positive breast cancer treatment. In the EU, Pebrilzo is authorized with trastuzumab and chemotherapy as neoadjuvant treatment for adults with high-risk, HER2-positive locally advanced, inflammatory, or early-stage breast cancer and as adjuvant treatment for adults with high-risk, HER2-positive early breast cancer.¹ It is also authorized with trastuzumab and docetaxel for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.¹
Biocon noted that about 15% to 20% of invasive breast cancers involve HER2 overexpression or amplification.¹
Where does Pebrilzo stand in the US?
FDA approved Pebrilzo (pertuzumab-qcay) as a biosimilar to Perjeta on November 16, 2026.⁴ Biocon also announced a global settlement and license agreement with Genentech that secures the earliest licensed US launch date for Pebrilzo in the third quarter of calendar year 2028.⁴
What happens next?
Biocon has not disclosed European launch timing. As the first biosimilar approval under the tailored pathway, Pebrilzo is likely to be watched as a test case by other biosimilar developers weighing whether to skip comparative efficacy studies for their own EU filings.
References
- Biocon’s pertuzumab gets marketing authorization in EU, first biosimilar approved under new tailored clinical approach. News release. Biocon; November 18, 2026. Accessed November 18, 2026.
- European Medicines Agency. Reflection paper on a tailored clinical approach in biosimilar development. Adopted March 16, 2026. Accessed November 18, 2026.
- EMA adopts landmark reflection paper on tailored clinical approach for biosimilars. GaBI Online. April 8, 2026. Accessed November 18, 2026.
- Biocon secures USFDA approval for Pebrilzo, eyes US launch in Q3 2028. Medical Dialogues. November 2026. Accessed November 18, 2026.
Related to this article
November 12th, 2026
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
November 10th, 2026
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
November 17th, 2026
Danish biotech Commit Biologics closed a $60 million seed round led by Ackermans & van Haaren, with AbbVie Ventures and M Ventures joining, to advance COM002, a bispecific antibody that recruits complement rather than T cells to eliminate diseased cells.
November 17th, 2026
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
November 17th, 2026
Mazen Noureddin, MD, MHSc, discusses phase 2 data for GSK’s once-monthly efimosfermin presented at The Liver Meeting 2026, including fibrosis marker results in patients with compensated cirrhosis.
November 16th, 2026
FDA declined to approve Summit Therapeutics and Akeso’s ivonescimab plus chemotherapy in previously treated EGFR-mutated NSCLC. The agency said the Phase 3 HARMONi trial’s progression-free survival benefit was not enough without a significant overall survival gain.
November 16th, 2026
Obinutuzumab produced complete proteinuria remission in 36.1% of primary membranous nephropathy patients at 2 years vs 5.7% with tacrolimus.
November 16th, 2026
Once-weekly self-injected gefurulimab improved daily-living scores in AChR-positive generalized myasthenia gravis in the 260-patient PREVAIL trial.
来源:BioPharm International · biopharminternational.com







